Newswise News from Sciele Pharma, A Shionogi Company and Plethora Solutions Holdings PLC Latest news from Sciele Pharma, A Shionogi Company and Plethora Solutions Holdings PLC on Newswise en-us Copyright 2024 Newswise Newswise News from Sciele Pharma, A Shionogi Company and Plethora Solutions Holdings PLC 115 31 / /images/newswise-logo-rss.gif Pivotal Study for PSD502--The First Potential Treatment for Premature Ejaculation /articles/pivotal-study-for-psd502-the-first-potential-treatment-for-premature-ejaculation/?sc=rsin /articles/pivotal-study-for-psd502-the-first-potential-treatment-for-premature-ejaculation/?sc=rsin Thu, 19 Nov 2009 08:00:00 EST At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc. today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Sciele Pharma, A Shionogi Company and Plethora Solutions Holdings PLC